Aptevo Therapeutics(APVO) - 2024 Q4 - Annual Results

Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE 100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues Promising Data, including a 59% Stable Disease Rate, in ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Makes the Case for Continued Development of First-in-Class Anti-Cancer Agent SEATTLE, WA – February 14, 2025 – Aptevo Therap ...